The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group.

摘要: BACKGROUND The role of doxorubicin (Doxo) as part multidrug regimens used to treat children with soft tissue sarcoma (STS) is controversial. To evaluate the feasibility combining Doxo well established ifosfamide, vincristine, and actinomycin D (IVA) regimen, Italian STS Committee performed a pilot study on series metastatic STS. METHODS Between July 2002 February 2004, 29 evaluable patients were enrolled in this study; 19 had rhabdomyosarcoma, 5 peripheral neuroectodermal tumor, other types STS. The IVA-Doxo (IVADo) regimen included ifosfamide 3 g/m2 Days 1 2, vincristine 1.5 mg/m2 Day 1, 30 2. Three courses IVADo be administered initial treatment analyzed for toxicity tumor response. RESULTS Overall, 92 cycles delivered. Major regimen-related was myelosuppression, Grade 4 neutropenia 67% fever 37% cycles. Nonhematologic 3–4 mucositis (6.5% cycles), constipation (9.7%), neuropathy (6.5%). Other manifestations major venoocclusive disease seizures, which occurred one patient each. All but malignant schwannoma showed some degree volume reduction; however, considering only complete partial remissions, response rate 76% (± 7.9%). CONCLUSIONS The intensive effective against pediatric acceptable toxicity. This combination will investigated high-risk rhabdomyosarcoma randomized trial launched by European Soft Study Group. Cancer 2005. © 2005 American Society.